Bijuva® 1/100

Theramex Menopause Education for Australian Health Care Professionals

Please note the above recordings have been edited from their original form to ensure compliance with regulatory requirements and remove any off-label content. The information presented is intended for Australian healthcare professionals only and may be considered promotional in nature.

The above livestream event recordings were organised and sponsored by Theramex Australia.

These were educational events for Australian health care professionals.

The final presentation content, as well as views and opinions expressed during the events are those of the speakers and do not necessarily reflect the views or positions of any entities they currently or have previously represented.

PBS Information: Bijuva® and Intrarosa® are not listed on the PBS

PLEASE REVIEW THE PRODUCT INFORMATION BEFORE PRESCRIBING.

Bijuva® Product Information: Full Product Information is available from Medical Information:1800 THERAMEX (1800 843 726) or online via https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2022-PI-01574-1&d=20240729172310101

Bijuva® 1/100 is indicated for use during continuous combined hormone replacement therapy (HRT) for estrogen deficiency symptoms in postmenopausal women with an intact uterus and with at least 12 months since last menses

Intrarosa® Product Information: Full Product Information is available from Medical Information:1800 THERAMEX (1800 843 726) or online via https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2023-PI-01802-1&d=20240308172310101

Intrarosa® is indicated for the treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms

▼Intrarosa® is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

Theramex Australia 2024. Level 22, 60 Margaret Street, Sydney NSW 2000. www.theramex.com.au.

PBS Information: This product is not listed on the PBS

PLEASE REVIEW THE PRODUCT INFORMATION BEFORE PRESCRIBING. Full product information is available from Medical Information: 1800 THERAMEX (1800 843 726)

Bijuva® 1/100 Minimum Product Information: This product contains a boxed warning, please visit the product information online or via Medical Information for full details. Bijuva® 1 mg of estradiol (as hemihydrate) and 100 mg of progesterone. Indication: Continuous combined hormone replacement therapy (MHT/HRT) for estrogen deficiency symptoms in postmenopausal women with an intact uterus and with at least 12 months since last menses. Contraindications: Known, past or suspected breast cancer; known or suspected estrogen-dependent malignant tumours; undiagnosed genital bleeding; untreated endometrial hyperplasia; venous thromboembolism; known thrombophilic disorders; active or recent arterial thromboembolic disease; acute liver disease or a history of liver disease as long as liver function tests have failed to return to normal; Porphyria; known hypersensitivity to the active substances or to any of the excipients. Precautions: Appraisal of the risks and benefits should be undertaken at least annually. Before initiating, a complete personal and family medical history should be taken. Refer to full product information for conditions that require supervision during treatment. Immediate withdrawal of therapy should be applied in the following situations: Jaundice or deterioration in liver function, significant increase in blood pressure, new onset of migraine-type headache, pregnancy. Cautions: Endometrial hyperplasia and carcinoma, breast cancer, ovarian cancer, venous thromboembolism, coronary artery disease (CAD), ischemic stroke, thyroid hormone levels, use in renal impairment, use in elderly, pediatric use. Interactions: The metabolism of estrogens and progestogens may be increased by use of drug-metabolizing enzymes, specifically cytochrome P450 enzymes, such as anticonvulsants, rifampicin, rifabutin, nevirapine, efavirenz, and griseofulvin, St John’s Wort, ritonavir, nelfinavir. Adverse Events: breast tenderness, headache, nausea, pelvic pain, vaginal haemorrhage and vaginal discharge (see PI for others) Dosage: Take one capsule each evening with food.References: 1. BIJUVA® (estradiol and progesterone capsules) Approved Product Information May 2025. 2. Davis SR, et al. Climacteric. 2023 Dec;26(6):517-536. 3. The 2022 hormone therapy position statement of The North American Menopause Society (NAMS)  Menopause 29(7) 767-794. 4. Lundberg MD et al. American College of Cardiology. 2019 July. 5. Hamoda et al. Post Reprod Health. 2020 Dec;26(4):181-209. 6. García-Sáenz M et al J. Clin. Med. 2023, 12, 3388. 7. AMS Guide to MHT/HRT Doses Australia only – Australasian Menopause Society, accessed January 2025. 8. Theramex Data on File, February 2024. 9. Black D 2020 NAMS Practice Pearl. Menopause 27(11) 1328-29. 10. Eden J. O&G Magazine (Menopause) 2017. 19(1) 11. Lobo RA, et al. Obstet Gynecol. 2018 Jul;132(1):161-170. 12. Kagan et al. Menopause. 2018 Dec 21;26(6):622-628.

Sponsored in Australia by Theramex Australia Pty Ltd,
ABN 37 623 186 845, 60 Margaret Street, Sydney, NSW 2000.
www.theramex.com.au;
Date of preparation, September 2025; BIJUVA_AU_EN_21618_v2.